A pharmaceutical company's success with a Phase 2 study doesn't guarantee positive results in Phase 3.Heading into 2026 on an inauspicious note, Ultragenyx Pharmaceuticals (RARE 43.70%), a pharmaceutical company specializing in treatments for rare and ultra-rare genetic diseases, announced disappointing results from its Phase 3 studies for setrusumab (UX143). Add in a flurry of analysts slashing their price targets on Ultragenyx stock, and it's clear why investors are clicking the sell button today.As of 2: ...